Robert Wasserman
Stock Analyst at Benchmark
(3.35)
# 970
Out of 5,067 analysts
111
Total ratings
48.6%
Success rate
2.62%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $49.26 | +11.65% | 7 | Nov 3, 2025 | |
| ITGR Integer Holdings | Downgrades: Hold | n/a | $71.22 | - | 12 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $74.00 | +21.62% | 10 | Sep 24, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $4 → $1.5 | $0.42 | +256.13% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $63.49 | +18.13% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $6.83 | +119.62% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.73 | +246.82% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $31.73 | +10.31% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.57 | - | 6 | Mar 3, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $26.35 | +13.85% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $8 | $2.37 | +238.07% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $4.87 | +2.67% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $10.81 | +11.01% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.59 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $167.26 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.55 | +12.68% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.26 | +1,423.23% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $2.57 | +2,823.98% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $226.98 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $586.07 | -1.04% | 1 | Jul 16, 2021 |
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $49.26
Upside: +11.65%
Integer Holdings
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $71.22
Upside: -
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75 → $90
Current: $74.00
Upside: +21.62%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4 → $1.5
Current: $0.42
Upside: +256.13%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $63.49
Upside: +18.13%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.83
Upside: +119.62%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.73
Upside: +246.82%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $31.73
Upside: +10.31%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.57
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $26.35
Upside: +13.85%
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.37
Upside: +238.07%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $4.87
Upside: +2.67%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $10.81
Upside: +11.01%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.59
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $167.26
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.55
Upside: +12.68%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.26
Upside: +1,423.23%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $2.57
Upside: +2,823.98%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $226.98
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $586.07
Upside: -1.04%